Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec™)

Leukemia Research

Volumn 34, Issue 6, 2010, Pages 827-829

  Gordon, Jessica K ^a   Magid, Steven K ^a   Maki, Robert G ^b   Fleisher, Martin ^b   Berman, Ellin ^b  

^a Hospital for Special Surgeryy   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adverse effect; Creatine kinase; Imatinib; Muscular disease; Rhabdomyolysis

Indexed keywords

DASATINIB; IMATINIB; STEROID;

ADULT; ANAMNESIS; ARM SWELLING; ARTICLE; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MALE; MYALGIA; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; CREATINE KINASE; EDEMA; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUSCULAR DISEASES; PIPERAZINES; PYRIMIDINES; UP-REGULATION; YOUNG ADULT;

EID: 77952095857     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.11.002     Document Type: Article

References (10)

1. Cohen M.H., Williams G., Johnson J.R., Duan J., Gobburu J., Rahman A., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002, 8:935-942.
2. [homepage on the internet]. Novartis Pharmaceuticals Corporation; c2008 [cited 2009 Oct 11]. Prescribing information at: http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf.
3. Franceschino A., Tornaghi L., Benemacher V., Assouline S., Gambacorti-Passerini C. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica 2008, 93:317-318.
4. Shimazaki C., Ochiai N., Uchida R., Fuchida S.I., Okano A., Ashihara E., et al. Intramuscular edema as a complication of treatment with imatinib. Leukemia 2003, 17:804-810.
5. Penel N., Blay J.Y., Adenis A. Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 2008, 358:2746-2747.
6. Berman E., Nicolaides N., Maki R., Fleisher M., Chanel S., Scheu K., et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. New Engl J Med 2006, 354:2006-2013.
7. Betsholtz C. Biology of platelet-derived growth factors in development. Birth Defects Res (Part C) 2003, 69:272-285.
8. Zhao Y., Haginoya K., Sun G., Dai H., Onuma A., Iinuma K. Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study. J Pathol 2003, 201:149-159.
9. Kerkelä R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908-916.
10. Huang P., Zhao X.S., Fields M., Ransohoff R.M., Zhou L. Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J 2009, 23(8):2539-2548.